MHRA-NICE Pathway Under Fire, Clinical Trial Targets Hit

Episode 13 — 27 May 2026 LSE expert challenges the new UK aligned drug approval pathway as industry-favoring while EU reports progress on 2030 clinical trial targets. NICE approves first HER2-targeted therapy for bile duct cancer as regulatory reforms reshape the clinical research landscape. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_01 0:00

Welcome to Access Brief, the daily AI podcast on HEOR HTA and Market Access. I'm Marcus with Sarah. Today, LSE criticism of the MHRA NICE Aligned Pathway, EU progress on clinical trial targets, and NICE's XANA datamab approval for bile duct cancer. Let's get into it.

SPEAKER_00 0:17

Starting with the aligned pathway controversy. Hussein Natchi from LSE published a sharp critique in the BMJ, arguing the new MHRA NICE collaboration benefits industry over patients and the NHS. His core point, they're running two independent processes in parallel without truly aligning evidentiary standards.

SPEAKER_01 0:36

The evidence gap is real. MHRA focuses on clinical effectiveness and safety, while NICE assesses comparative effectiveness and value for money. These aren't the same thing. And pretending synchronization equals alignment is misleading. When you have 27 companies signed up as early adopters with first guidance expected next month, the pressure to show success is enormous.

SPEAKER_00 1:01

But Marcus, isn't this exactly what industry has been asking for? The pathway promises delivery three, six months earlier. That's meaningful for patients waiting for new treatments, regardless of whether the evidentiary bars are perfectly aligned.

SPEAKER_01 1:14

Earlier access to what, though? If NICE is still applying its value framework independently, we could see more situations where MHRA approves but NICE rejects. That doesn't help patients. It creates false hope and wastes NHS resources on regulatory theater.

SPEAKER_00 1:29

The EU clinical trial targets tell a different story about regulatory efficiency. The first progress report shows 19 additional multinational trials authorized above historical averages in just the first quarter. They're tracking toward 500 extra trials by 2030, with 40.5% of trials recruiting within 200 days from application.

SPEAKER_01 1:49

Those numbers look encouraging, but let's see the sustainability. Adding 19 trials in three months extrapolates to maybe 76 annually. We'd need six times that pace to hit 500 extra by 2030. The 40.5% recruitment rate within 200 days also suggests the majority still take longer.

SPEAKER_00 2:07

Fair point on the math, but the systematic tracking itself represents progress. The EU is finally measuring what it wants to achieve rather than just setting aspirational targets.

SPEAKER_01 2:17

Meanwhile, the UK's clinical trials regulatory overhaul came into force last month, the most significant change in 20 years. Moving from amendments to modifications and introducing modification of important detail categories should reduce researcher burden while maintaining safety standards.

SPEAKER_00 2:36

The terminology shift to align with EU practices is smart politics, especially given Brexit's research collaboration challenges. But I'm watching how modification of important detail gets interpreted in practice. Requiring notification but not approval could speed things up or create confusion about what constitutes important.

SPEAKER_01 2:55

The ICH good clinical practice compliance requirement is the bigger change. That's a real evidentiary standard, not just procedural reshuffling.

SPEAKER_00 3:04

Shifting to outcomes. NICE's Xanodatimub approval for bile duct cancer is clinically impressive. Average survival of 18 months versus six months with standard chemotherapy means tripling survival times for approximately 65 patients annually in England.

SPEAKER_01 3:19

The evidence is strong, but let's be clear about what we're celebrating. This is the first her two-targeted therapy for biliary tract cancer, so the comparator bar was low. And with only 65 eligible patients annually, the budget impact calculation was straightforward for NICE.

SPEAKER_00 3:37

You're underselling the operational benefit. Avoiding surgically implanted devices required for FL Fox chemotherapy reduces hospital capacity pressures. That's real value beyond the QLI calculation.

SPEAKER_01 3:48

True, though I'd want to see the data on actual resource utilization differences before factoring that heavily into access decisions.

SPEAKER_00 3:56

The EU JCA updates from last week show implementation continues evolving. New FAQs about report publication and guiding principles on data transparency suggest they're learning from the first year of mandatory assessments.

SPEAKER_01 4:09

Learning or struggling. These updates typically emerge when the original framework isn't working as intended. We're approaching the second year of operation and still publishing guidance clarifications.

SPEAKER_00 4:21

That's the reality of any major regulatory shift. Better to iterate based on experience than stick rigidly to an imperfect initial design.

SPEAKER_01 4:28

The broader theme this week is regulatory bodies trying to balance speed with rigor. Whether it's the UK's aligned pathway, EU clinical trial targets, or JCA implementation refinements, everyone's chasing efficiency gains.

SPEAKER_00 4:42

The question is whether these efficiency gains translate to better patient outcomes or just faster industry timelines. Next week should bring the first MHRA nice aligned pathway guidance. That'll be our real test case.

SPEAKER_01 4:54

Back tomorrow on Access Brief. Show notes at outcomes analytica.noblow.